| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2025-097 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于全资子公司获得枸橼酸莫沙必利片 二、药品的其他相关情况 1 3、规格： 5mg（按 C21H25ClFN3O3·C6H8O7计） 4、申请事项：药品注册（境内生产） 5、注册分类：化学药品 4 类 6、受理号：CYHS2400126 7、药品批准文号：国药准字 H20255193 8、药品批准文号有效期：至 2030 年 08 月 25 日 9、上市许可持有人：宁波美诺华天康药业有限公司 10、生产企业：宁波美诺华天康药业有限公司 药品适应症：用于改善因胃肠动力减弱（如：功能性消化不良、慢性胃炎） 引起的消化道症状，包括烧心、嗳气、恶心、呕吐、早饱、上腹胀、上腹痛等。 药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波美诺华药业股份有限公司（以下简称"公司"）全资子公司宁波美诺华 天康药业有 ...

Core Viewpoint - Meinuohua (603538.SH) announced that its wholly-owned subsidiary, Ningbo Meinuohua Tiankang Pharmaceutical Co., Ltd., has received the drug registration certificate for Mosapride Citrate Tablets from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product [1] Group 1 - The drug is indicated for improving gastrointestinal symptoms caused by decreased gastrointestinal motility, such as functional dyspepsia and chronic gastritis [1] - Symptoms addressed by the drug include heartburn, belching, nausea, vomiting, early satiety, upper abdominal bloating, and upper abdominal pain [1]

Core Viewpoint - Meihua's subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration certificate of Mosapride Citrate Tablets, which are indicated for improving gastrointestinal symptoms caused by reduced gastrointestinal motility [1] Group 1 - The approved drug is intended for symptoms such as heartburn, belching, nausea, vomiting, early satiety, upper abdominal distension, and upper abdominal pain [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company has shown significant growth in its main business, with a notable increase in revenue and net profit in the first half of 2025, indicating a turning point in its operations [5] - The company is expected to achieve substantial revenue growth in the coming years, driven by its innovative business layout and expansion in various segments [5] Summary by Relevant Sections Financial Performance - In the first half of 2025, the company achieved revenue of 677 million yuan, a year-on-year increase of 11.42%, and a net profit attributable to shareholders of 49 million yuan, up 158.97% [5] - The second quarter of 2025 saw revenue of 401 million yuan, a year-on-year growth of 16.15%, and a net profit of 28 million yuan, reflecting a significant increase of 468.03% [5] - The gross margin for the first half of 2025 was 32.45%, an increase of 2.94 percentage points, while the net margin was 7.84%, up 4.34 percentage points [5] Business Segments - The formulation segment reported revenue of 262 million yuan in the first half of 2025, a year-on-year increase of 111.03%, driven by the successful commercialization of its projects [5] - The active pharmaceutical ingredient (API) business is stabilizing, with new product registrations ongoing, and the company has established solid supply relationships with major pharmaceutical firms [5] - The CDMO (Contract Development and Manufacturing Organization) segment is expanding, with ongoing collaborations with major clients and new project developments [5] Future Outlook - Revenue projections for 2025-2027 are 1.603 billion, 1.982 billion, and 2.389 billion yuan, with year-on-year growth rates of 16.77%, 23.69%, and 20.49% respectively [5] - The net profit attributable to shareholders is expected to reach 129 million, 164 million, and 208 million yuan for the same period, with growth rates of 92.98%, 27.16%, and 27.04% respectively [5] - The company's stock is currently trading at a price-to-earnings ratio (P/E) of 23, 18, and 14 for the years 2025, 2026, and 2027, respectively, indicating a favorable valuation given the expected growth [5]

Meeting Information - The first temporary shareholders' meeting of Ningbo Meinuo Pharmaceutical Co., Ltd. will be held on September 11, 2025, at 14:00 in Ningbo, Zhejiang Province [1] - The voting method will combine on-site and online voting, with specific time slots for each [1] Meeting Agenda - The agenda includes a proposal to abolish the supervisory board and amend the company's articles of association [4][5] - The proposal has been approved by the company's board of directors and supervisory board [5] Voting Procedures - Shareholders must sign in 10 minutes before the meeting and present necessary identification [2] - Voting will be conducted through a named voting method, and any blank votes will be considered abstentions [3] Legal Compliance - The meeting will be conducted in accordance with the Company Law of the People's Republic of China, the Securities Law, and the company's articles of association [2][4] - A lawyer will be present to provide legal opinions on the meeting's compliance with relevant laws [4][5] Proposal Details - The proposal to abolish the supervisory board will transfer its responsibilities to the audit committee of the board of directors [4] - Amendments to the articles of association will reflect this change and have been prepared in a draft for review [5] Shareholder Rights - Shareholders have the right to participate in discussions related to the agenda and vote accordingly [2][3] - The company will ensure that the meeting is conducted in a serious and orderly manner, allowing only authorized personnel to attend [2]

宁波美诺华药业股份有限公司 2025 年第一次临时股东大会会议资料 宁波美诺华药业股份有限公司 2025 年第一次临时股东大会会议资料 中国·宁波 二○二五年九月十一日 1 | | | 宁波美诺华药业股份有限公司 2025 年第一次临时股东大会会议资料 会 议 议 程 一、会议时间、地点 召开时间：2025 年 9 月 11 日，14：00 召开地点：浙江省宁波市高新区扬帆路 999 弄研发园 B1 号楼 12A 层 1 号会议室 二、会议议程 1、会议主持人宣布大会开始，推选计票人、监票人各两名； 2、董事会秘书宣读大会会议须知； 3、会议主持人介绍会议议案： | 序号 | 议案名称 | | --- | --- | | 非累积投票议案 | | | 1 | 关于撤销监事会并修订《公司章程》的议案 | | 2.00 | 关于修订、制定公司部分管理制度的议案 | | 2.01 | 股东会议事规则 | | 2.02 | 董事会议事规则 | | 2.03 | 独立董事工作制度 | | 2.04 | 对外投资管理制度 | | 2.05 | 对外担保管理制度 | | 2.06 | 关联交易管理制度 | | 2.07 | ...

Group 1 - Menova's stock price increased by 5.84% to 27.56 CNY per share, with a trading volume of 439 million CNY and a turnover rate of 7.71%, resulting in a total market capitalization of 6.058 billion CNY [1] - Menova's main business includes the research, production, and sales of specialty raw materials (including intermediates) and finished drugs, with revenue composition as follows: intermediates and raw materials 57.74%, formulations 29.53%, CDMO 8.87%, trade 3.52%, and others 0.34% [1] Group 2 - Wan Jia Fund has one fund heavily invested in Menova, specifically the Wan Jia Guo Zheng 2000 ETF, which held 201,800 shares in the second quarter, accounting for 0.49% of the fund's net value, making it the second-largest holding [2] - The Wan Jia Guo Zheng 2000 ETF has a total size of 808 million CNY and has achieved a year-to-date return of 29.99%, ranking 1313 out of 4223 in its category, with a one-year return of 76.26%, ranking 872 out of 3780 [2]

Core Viewpoint - Meinuo's stock price dropped by 8.18% on the trading day, with significant institutional selling and a high turnover rate, indicating potential market concerns about the company's performance and investor sentiment [2][3]. Trading Performance - The stock had a turnover rate of 18.01% and a trading volume of 1.017 billion yuan, with a price fluctuation of 9.40% throughout the day [2]. - Institutional investors net sold 57.48 million yuan, while the total net selling from brokerage seats amounted to 55.29 million yuan [2]. Institutional Activity - The stock was listed on the Shanghai Stock Exchange's watch list due to a daily price deviation of -9.32% [2]. - The top five brokerage seats accounted for a total transaction of 252 million yuan, with a net selling amount of 113 million yuan [2]. Recent Financial Performance - For the first half of the year, Meinuo reported a revenue of 677 million yuan, representing a year-on-year growth of 11.42%, and a net profit of 49.06 million yuan, which is a significant increase of 158.97% [3]. Margin Trading Data - As of August 27, the margin trading balance for Meinuo was 416 million yuan, with a financing balance of 416 million yuan and a small securities lending balance of 0.57 million yuan [3]. - Over the past five days, the financing balance decreased by 32.76 million yuan, a decline of 7.30%, while the securities lending balance increased by 0.29 million yuan, a rise of 104.25% [3].

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.45% on August 28, with Nanjing New Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Top Performers - Duorui Pharmaceutical (301075) saw a closing price of 44.40, with a rise of 7.87% and a trading volume of 59,400 shares, totaling a transaction value of 259 million [1] - Guangshengtang (300436) closed at 131.39, up 5.49%, with a trading volume of 172,000 shares and a transaction value of 2.192 billion [1] - Xingqi Eye Medicine (300573) closed at 68.70, increasing by 3.71%, with a trading volume of 318,800 shares and a transaction value of 2.239 billion [1] Underperformers - Nanjing New Pharmaceutical (681899) closed at 15.41, down 9.25%, with a trading volume of 455,800 shares and a transaction value of 701 million [2] - Meinuohua (603538) closed at 26.04, down 8.18%, with a trading volume of 387,900 shares and a transaction value of 1.017 billion [2] - Borui Pharmaceutical (688166) closed at 98.04, down 6.63%, with a trading volume of 225,300 shares and a transaction value of 2.201 billion [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 3.702 billion from institutional investors, while retail investors contributed a net inflow of 3.086 billion [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Huadong Pharmaceutical (000963) had a net inflow of 89.0375 million from institutional investors, while retail investors saw a net outflow of 84.9691 million [3] - Guangshengtang (300436) experienced a net inflow of 52.2637 million from institutional investors, with retail investors also seeing a net outflow of 25.6366 million [3] - Nanjing New Pharmaceutical (688189) had a net inflow of 17.9937 million from institutional investors, while retail investors faced a net outflow of 41.5515 million [3]

Group 1 - The weight loss drug concept stocks experienced a decline in the afternoon trading session on August 28, with Meinuohua hitting the daily limit down [1] - MediXy and Kangyuan Pharmaceutical both fell over 7%, indicating a significant drop in their stock prices [1] - Other companies such as Kexing Pharmaceutical and Haixiang Pharmaceutical also reported notable declines in their stock performance [1]